DEF 14A: Chimerix Seeks Stockholder Approval for 2024 Equity Incentive Plan

Chimerix is asking stockholders to approve the 2024 Equity Incentive Plan to replace the 2013 plan and attract key talent.

Summary

• Chimerix is seeking stockholder approval for the Chimerix, Inc. 2024 Equity Incentive Plan (the 2024 Plan) at the upcoming Annual Meeting on June 20, 2024.
• The 2024 Plan is intended to succeed the Chimerix, Inc. 2013 Equity Incentive Plan (the 2013 Plan).
• If approved, no further awards will be granted under the 2013 Plan, and available shares will roll over to the 2024 Plan.
• The company is requesting 10,182,331 new shares for the 2024 Plan.
• The 2024 Plan includes provisions designed to protect stockholder interests, such as minimum vesting requirements, no repricing without stockholder approval, and clawback policies.
• As of April 22, 2024, there were 19,770,106 shares subject to outstanding stock options with a weighted-average exercise price of $4.39.
• The burn rate for 2023 was 4.99%, calculated as (shares subject to stock options granted + shares subject to full value awards granted) / weighted average common stock outstanding.
• The board recommends voting in favor of the 2024 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral tone. The focus is on corporate governance and executive compensation, with a generally positive outlook on the company's future.

Positives

• The 2024 Plan includes provisions designed to protect stockholder interests, such as minimum vesting requirements, no repricing without stockholder approval, and clawback policies.
• The company manages its equity award use carefully.
• The size of the share reserve request is considered reasonable.

Negatives

• All of the named executive officers' stock options granted in 2023 and earlier had exercise prices that were above market price of the underlying stock as of December 31, 2023.

Risks

• If the stockholders do not approve the 2024 Plan, the 2013 Plan will continue to be effective in accordance with its terms.
• Equity awards dilute existing stockholders.

Future Outlook

The company's long-term business strategy is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases and to deliver long-term value creation for its stockholders.

Management Comments

• The continuing management team has hands-on experience with our repositioning as an oncology-focused company and has shown strong commitment to increasing stockholder value by executing the Company's growth strategy.

Industry Context

The peer group used for compensation benchmarking includes Allovir, Kronos Bio, ALX Oncology, MEI Pharma, Arcturus Therapeutics, Precision BioSciences, Ardelyx, Rain Oncology, BioXcel Therapeutics, Seres Therapeutics, Curis, Sesen Bio, CymaBay Therapeutics, Surface Oncology, CytomX Therapeutics, Trevena, G1 Therapeutics, VBI Vaccines, Gritstone bio, and Y-mAbs Therapeutics.

Comparison to Industry Standards

• The 2023 peer group was recommended by Aon and compiled by selecting companies with the following parameters: operating in the biopharmaceutical industry, with a focus on Phase 3 companies with a preference given to companies with an oncology focus, with market capitalizations and headcounts generally from one-third to three times our market capitalization and headcount.
• The company's TSR ranked above the median of its 2023 peer group (84th percentile) while its CEO's realizable compensation ranked below the median of its 2023 peer group (28th percentile).

Management Changes

Corporate Governance

Stakeholder Impact

• Approval of the 2024 Equity Incentive Plan is intended to align the interests of employees, directors, and consultants with the interests of stockholders.
• The executive compensation program is designed to reward financial, strategic, and operational performance, supporting the company's long-range plans.

Next Steps

• Stockholder vote on the 2024 Equity Incentive Plan at the Annual Meeting on June 20, 2024.
• Election of three Class II Directors at the Annual Meeting.
• Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.

Key Dates

Keywords

Equity Incentive Plan, Stock Options, Restricted Stock Units, Executive Compensation, Chimerix, Share Reserve, Burn Rate, Clawback Policy, Proxy Statement, Corporate Governance